Syngene International names Siddharth Mittal CEO, Kiran Shaw chair
Verified article - details checked for accuracy.
Syngene International names Kiran Mazumdar Shaw as executive chair and Siddharth Mittal as CEO, with changes taking effect in early‑mid 2026.
- Peter Bains will step down as Managing Director & CEO on 30 June 2026.
- Kiran Mazumdar Shaw shifts from non‑executive to executive chairperson on 1 April 2026, for a five‑year term.
- Siddharth Mittal assumes the Managing Director & CEO role and an Additional Director seat on 1 July 2026, also for a five‑year term; he joins from Biocon Biologics with M&A and strategic finance experience.
- The new team will sharpen focus on biosimilars, complex peptides and GLP‑1 therapeutics; all appointments await shareholder approval under SEBI Listing Regulation 30.
Complete ArticleExclusive Frism Intelligence Report
Frism is a financial information and news discovery platform. We provide factual summaries and data correlations for educational and informational purposes only. Frism does not provide investment advice, buy/sell recommendations, or directional market outlooks. Users should consult a qualified financial advisor before making any investment decisions.